糖尿病与非糖尿病牙周炎患者对SRP联合甲硝唑和阿莫西林治疗的临床与微生物学效应:队列研究
本研究纳入29例2型糖尿病和29例非糖尿病重度牙周炎患者,均接受SRP联合甲硝唑400mg每日三次和阿莫西林500mg每日三次治疗14天。1年时两组达到临床终点(≤4个位点PD≥5mm)的比例分别为75.9%和68.9%(p>0.05),但糖尿病组临床附着获得较低且红色和橙色复合菌比例较高(p<0.05)。结论为非糖尿病患者的应答并未优于糖尿病患者。
要点
- SRP联合甲硝唑和阿莫西林治疗14天,糖尿病与非糖尿病重度牙周炎患者1年临床终点达成率无显著差异。
- 糖尿病组临床附着获得较低,红色和橙色复合菌比例较高,愈合更依赖牙龈退缩。
- 非糖尿病患者的临床和微生物学应答并未优于2型糖尿病患者。
核心结论
- 非糖尿病重度牙周炎患者对SRP+MTZ+AMX治疗的应答并未优于2型糖尿病患者,临床终点达成率和PD改善均无显著差异。
- 糖尿病患者的微生物学应答稍差,愈合过程更多与牙龈退缩相关。
研究设计与样本
- 队列研究,纳入29例2型糖尿病和29例非糖尿病重度牙周炎患者。
- 所有患者接受SRP+甲硝唑400mg每日三次+阿莫西林500mg每日三次,共14天。
- 基线、治疗后3、6、12个月进行临床和微生物学监测,龈下生物膜样本采用棋盘DNA-DNA杂交分析40种细菌。
主要发现
- 非糖尿病组和糖尿病组分别有68.9%和75.9%的患者在治疗后1年达到临床终点(≤4个位点PD≥5mm),组间比较p>0.05。
- 糖尿病组从基线至治疗后1年的平均临床附着获得低于非糖尿病组(p<0.05)。
- 糖尿病组红色和橙色复合菌的平均比例高于非糖尿病组(p<0.05)。
关键数值与推荐
- 临床终点定义为≤4个位点探诊深度(PD)≥5mm。
- 甲硝唑剂量为400mg每日三次,阿莫西林剂量为500mg每日三次,疗程14天。
临床怎么用
- 对于2型糖尿病合并重度牙周炎患者,SRP联合甲硝唑和阿莫西林治疗可考虑使用,但需预期其微生物学应答可能稍差且愈合更依赖牙龈退缩。
- 非糖尿病患者使用该联合方案并未显示额外优势,临床决策应综合考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate if non-diabetic subjects with periodontitis respond better than subjects with type 2 diabetes to the treatment protocol of scaling and root planing (SRP), metronidazole (MTZ) and amoxicillin (AMX). MATERIAL AND METHODS: Diabetic and nondiabetic subjects with severe periodontitis received SRP + MTZ (400 mg/thrice a day [TID]) + AMX (500 mg/TID) for 14 days. Subgingival biofilm samples were analyzed by checkerboard DNA-DNA hybridization for 40 bacterial species. Subjects were monitored at baseline, 3, 6 and 12 months post-therapy. RESULTS: Twenty-nine type 2 diabetics and 29 non-diabetic subjects participated of this study. Of the non-diabetics and diabetics, 68.9% and 75.9%, respectively, reached the clinical endpoint for treatment (≤4 sites with probing depth [PD] ≥5 mm) at 1 year post-therapy (p > 0.05). The diabetic group presented lower mean clinical attachment gain from baseline to 1 year post-therapy and higher mean proportions of the red and orange complexes than the non-diabetic group (p < 0.05). CONCLUSIONS: Non-diabetic subjects with severe periodontitis did not respond better than type 2 diabetic subjects to the treatment protocol of SRP + MTZ + AMX, both in terms of achieving the clinical endpoint for treatment and of PD improvement. Diabetic subjects exhibited a slightly worse microbiological response and showed a healing process more associated with gingival recession than the non-diabetics.
引用
- Duarte PM, Feres M, Yassine LLS, et al. Clinical and microbiological effects of scaling and root planing, metronidazole and amoxicillin in the treatment of diabetic and non-diabetic subjects with periodontitis: A cohort study. J Clin Periodontol. 2018. PMID: 30076615. doi:10.1111/jcpe.12994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。